Isoquinoline-Steroid Conjugates for Ocular Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular inflammatory diseases, such as uveitis, often rely on steroidal anti-inflammatory medications that can increase intraocular pressure, leading to side effects like glaucoma and cataracts, and have limited water solubility, necessitating a more effective and safer alternative.
Innovation Solution
Development of isoquinoline-steroid conjugates, specifically compounds of Formula (I) and their derivatives, which modulate kinase activity, particularly ROCK and JAK kinases, to treat ocular inflammatory diseases without elevating intraocular pressure, thereby reducing the risk of glaucoma and cataracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal anti-inflammatory medication is used to treat ocular inflammatory diseases, then inflammation is reduced, but intraocular pressure increases
Solution Approach 1:
The patent divides the steroid molecule into two separate components: a glucocorticoid fragment (providing anti-inflammatory activity) and a non-steroidal fragment (providing IOP reduction). This segmentation allows each component to independently fulfill its specific function without the harmful side effects of traditional steroids, resolving the contradiction between anti-inflammatory efficacy and intraocular pressure control
Solution Approach 2:
The patent merges the beneficial properties of glucocorticoids (anti-inflammation) with non-steroidal compounds (IOP reduction) into a single conjugate molecule. This combination achieves both anti-inflammatory efficacy and intraocular pressure reduction simultaneously, eliminating the need to choose between these two functions
2Reliability
If steroidal anti-inflammatory medication is used to treat ocular inflammatory diseases, then inflammation is reduced, but glaucoma risk increases
Solution Approach 1:
By separating the steroid into glucocorticoid and non-steroidal fragments, the patent eliminates the glaucoma-risk component while preserving the anti-inflammatory benefit, thus reducing glaucoma risk without sacrificing therapeutic efficacy
Solution Approach 2:
The patent converts the harmful side effect profile of traditional steroids (glaucoma, cataracts, IOP increase) into a beneficial profile by using the non-steroidal fragment to actively reduce IOP and eliminate the risk of glaucoma and cataracts while maintaining anti-inflammatory activity
3Reliability
If steroidal anti-inflammatory medication is used to treat ocular inflammatory diseases, then inflammation is reduced, but water solubility is limited
Solution Approach 1:
The patent creates a composite molecular structure combining glucocorticoid and non-steroidal fragments with complementary properties. The non-steroidal fragment contributes enhanced water solubility while the glucocorticoid fragment provides anti-inflammatory activity, achieving both therapeutic efficacy and improved pharmacokinetic properties
Data Source
AI summary
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.